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Abstract  
The use of a biological marker as an adjunct for screening for invasive aspergillosis 
(IA) in high-risk patients is attractive, because it is noninvasive and may detect evidence of 
IA prior to the appearance of clinical signs and symptoms. Galactomannan (GMN) is a 
polysaccharide cell-wall component that is released by Aspergillus species. In the present 
work, an electrochemical microfluidic immunosensor for GMN detection was developed.  
Moreover, copper nanoparticles covered with polyvinylpyrrolidone (CuNPs-PVP) were 
synthesized, characterized and used in a microfluidic immunosensor based on the use of 
anti-GMN antibodies as a trapping agent. The concentration of trapped GMN is then 
electrochemically quantified by HRP-conjugated anti-GMN-antibody. HRP reacted with its 
enzymatic substrate in a redox process which resulted in the appearance of a current whose 
magnitude is directly proportional to the concentration of GMN. The immunosensor was 
validated by analyzing patient samples, and a good correlation with a commercial ELISA 
was obtained. This microfluidic immunosensor can be applied to the early diagnosis of IA. 
 
Keywords: Galactomannan; invasive aspergillosis; clinical diagnosis; nano-platform; 
microfluidic immunosensor; electrochemical. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
3 
 
1. Introduction 
  The concept of aspergillosis involves a wide variety of infections, ranging from the 
aspergillosis bronchopulmonary allergic to the aspergillosis disseminated. Invasive 
aspergillosis (IA) is one of these infections that in immunocompetent people can cause 
allergic reactions, but in people, who have an immunocompromised state of health, the 
disease is invasive, serious and if it is not treated it can be fatal [1]. In recent decades, there 
has been a significant increase in the number of patients who have HIV, cancer patients, 
transplant patients or those who receive immunomodulatory drugs, that is why the rate of 
people suffering from IA has also increased [2]. 
 IA is caused by inhalation of spores of a type of mold called Aspergillus fumigatus 
[3]. This fungus can often be found in dead leaves, organic fertilizer and decomposing plant 
matter. Mold spores can be transported on shoes and clothes and can grow on the carpet of 
homes. Air conditioners are suitable places for mold growth if the filters are not kept clean 
and the water does not drain as it should. The walls of old houses may be contaminated 
with their spores [3]. The symptoms of IA can be nonspecific [4], causing cough, fever, 
hemoptysis, pleuritic pain, etc. Usually present one or more nodules with peribronchial 
infiltrate or pleural effusion. When this infection spreads to the brain it causes seizures, 
cerebral infarcts and meningitis [4]. Moreover, diagnosis of IA is challenging, because 
clinical and radiologic signs are very insensitive or nonspecific [4]. Tissue biopsy as a 
means of making the diagnosis is invasive and is not always possible, especially among 
patients with thrombocytopenia [3, 4]. Early diagnosis leading to prompt institution of 
appropriate therapy may result in improved patient outcomes. IA has many antigenic 
components, but the most useful is galactomannan (GMN) and its determination for the 
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early detection of this serious infection is relevant in the clinical diagnosis [4]. GMN is a 
heteropolysaccharide present in the cell wall of most Aspergillus species [4]. In the last 
years, much attention has been focused on developing a noninvasive test for diagnosing IA, 
particularly methods to detect GMN [3, 4]. Due to the risk of contamination and 
colonization of bacteria, especially sputum, detection of GMN in serum is better [4]. 
Currently, there is a commercial method for the detection of GMN called ELISA Platelia™ 
Aspergillus kit (Bio-Rad, France) which is a "sandwich" immunoenzymatic (EIA) assay 
[5]. This method that incorporates the β 1-5 galactofuranose-specific EBA2 monoclonal 
antibody as both the detector and acceptor for GMN showed a high sensitivity and has been 
approved by the US Food and Drug Administration for use with serum samples [5]. 
However, these methods consume a lot of time and need sophisticated instrumentation.  
 In recent years, electrochemical microfluidic immunosensors have been used in the 
clinical field, especially for the diagnosis of infectious diseases [6]. These devices are 
considered to be valuable and promising ones due to their robustness, simplicity, 
sensitivity, ease of handling, cost-effectiveness, rapid analysis and miniaturization ability 
[7-10]. Furthermore, when these microfluidic immunosensors are modified with 
nanoparticles acquire a greater selectivity than those naked sensors and also have the 
capacity to increase the sensitivity of the method due to the increase of the surface area that 
said nanoparticles provide [7]. The specific use of some metallic nanoparticles as such as 
copper nanoparticles (CuNPs) can be very interesting for the modification of the central 
channel of a microfluidic immunosensor and as platform for biomolecules immobilization 
(antigens, antibodies, enzymes or DNA) [7-15].   
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 In this work, we report a sensitive electrochemical microfluidic immunosensor 
based on copper nanoparticles covered with polyvinylpyrrolidone (CuNPs-PVP) as nano-
platform for anti-GMN monoclonal antibodies immobilization applied to specifically 
determination of the GMN present in serum samples. To the best of our knowledge, an 
electrochemical microfluidic immunosensor based on CuNPs-PVP as nano-platform and 
specific monoclonal antibodies for GMN quantification has not reported to date. 
 
2. Experimental 
2.1. Materials and reagents  
 The following materials and chemicals were used as supplied. Soda-lime glass 
wafers (26 × 76 × 1 mm) were purchased from Glass Technical (São Paulo, SP, Brazil). 
AZ4330 photoresist (PR) and AZ 400 K were obtained from Dow Corning (Midland, MI, 
USA) and Clariant Corporation (Sommerville, NJ, USA), respectively. Glutaraldehyde 
(25% aqueous solution) and hydrogen peroxide 30% were purchased from Merck 
(Darmstadt, Germany). Polyvinylpyrrolidone (PVP k30, Mw= 82,500), 
ethylenediamminetetraacetic acid (EDTA, C10H16N2O8), copper sulphate (CuSO4), sodium 
borohydride (NaBH4, 99.99%), hydrofluoric acid (HF), 3-aminopropyl triethoxysilane (3-
APTES) and 4-tert-butylcatechol (4-TBC) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). The commercial ELISA Platelia™ Aspergillus kit (enzyme immunoassay) for 
the quantitative determination of GMN was purchased from Bio-Rad (France), and it was 
used according to the manufacturer’s instructions. Mouse monoclonal specific antibody to 
GMN (1 mg mL
-1
) and HRP-conjugated anti-GMN-antibody (1 mg mL
-1
) were purchased 
from Agrisera (Sweden) and Abcam
®
 (USA), respectively. All buffer solutions were 
prepared with Milli-Q water. 
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2.2. Apparatus 
Amperometric measurements were performed using the BAS LC 4 C (Bioanalytical 
Systems, West Lafayette, IN, USA). The BAS 100 B electrochemical analyzer 
Bioanalytical Systems) was used for cyclic voltammetry analysis. 
The gold layer electrode was deposited at central channel (CC) by sputtering (SPI-
Module Sputter Coater with Etch mode, Structure probe Inc., West Chester, PA, USA) and 
the gold thickness electrode was measured using a Quartz Crystal Thickness Monitor model 
12161 (Structure probe Inc., West Chester, PA, USA).  
The synthesized CuNPs-PVP were characterized by UV-visible spectroscopy (UV-
visible spectrophotometer model UV-1650 PC – Shimadzu, USA), scanning electron 
microscope (SEM) (LEO 1450VP, UK), energy dispersive spectrometer (EDS) (EDAX 
Genesis 2000 energy dispersive spectrometer, England) and transmission electron 
microscopy (TEM) (Carl Zeiss CEM902, USA). Infrared (FTIR) spectroscopic 
measurements were obtained in a Spectrum 65 FIIR spectrometer Perkin Elmer, in a region 
from 4000 to 400 cm
-1
. Textural characterization was carried out by N2 adsorption-
desorption isotherms at 77 K using a manometric adsorption equipment (ASAP 2000, 
Micromeritics), where the samples were previously degassed at 250°C for 12 h, up to a 
residual pressure smaller than 3 Pa. 
A syringe pumps system (Baby Bee Syringe Pump, Bioanalytical Systems) was 
used for pumping, sample introduction, and stopping flow. 
All solutions and reagent temperatures were conditioned before the experiment 
using a Vicking Masson II laboratory water bath (Vicking SRL, Buenos Aires, Argentina). 
Absorbance was detected by Bio-Rad Benchmark microplate reader (Japan) and 
Beckman DU 520 general UV/ VIS spectrophotometer.  
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All pH measurements were made with an Orion Expandable Ion Analyzer (Orion 
Research Inc., Cambridge, MA, USA) Model EA 940 equipped with a glass combination 
electrode (Orion Research Inc.) 
 
2.3. Synthesis of nano-platform: CuNPs-PVP 
 CuNPs-PVP were synthesized by a chemical reduction method using NaBH4 with 
some own modifications [16]. CuSO4 (1 mM) and EDTA were dissolved in 25 mL of 
ultrapure water (MilliQ-Plus
®
) in which 10 mL of PVP (1 g L
-1
)
 
was added. Later, NaBH4 
(0.1 M) was added to the above solution as reducing agent, and then the solution was 
heated to 30°C under constant stirring for 30 min. After, the NPs solution was spilled out 
and filtered. Subsequently, the product was washed 3 times with ethanol and acetone 
separately and finally was sonicated for 30 min before use. Finally, the CuNPs-PVP were 
re-suspended in 1 mL of ultrapure water. 
 
2.4. Microfluidic immunosensor fabrication 
The construction of microfluidic immunosensor was carried out according to the 
procedure proposed by Moraes et al. (2012) with own modifications [17]. The microfluidic 
immunosensor design consisted of a T-type format with a central channel (CC) (60 mm 
length; 100 µm diameter) and accessory channels (15 mm length; 70 µm diameter). The 
main body of the microfluidic immunosensor was made of glass. Firstly the device layout 
was drawn using CorelDraw software version 11.0 (Corel Corporation) and printed on a 
high-resolution transparency film in a local graphic service, which was used as a mask in 
the photolithographic step.  The printed mask was placed on top of a glass wafer previously 
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coated with a 5 μm layer of AZ4330 (PR). The substrate was exposed to UV radiation for 
30 s and revealed in AZ 400 K developer solution for 2 min. Glass channels were obtained 
employing an etching solution consisted of 20% HF for 4 min under continuous stirring. 
The etching rate was 8±1 μm min-1. Following the etching step, substrates were rinsed with 
deionized water and the photoresist layer was removed with acetone. To access the 
microfluidic network, holes were drilled on glass-etched channels with a Dremel tool 
(MultiPro 395JU model, USA) using 1 mm diamond drill bits. For bonding of the chip, 
another glass plate with a thickness of 1 mm was used. The two pieces were thoroughly 
cleaned to avoid dust particles affecting the yield and they were brought into contact 
immediately at high temperature (typically above 500°C) for bonding steps, obtaining a 
strong irreversible sealing. The bonding resistance of the present device was evaluated 
under different pressure values by using a high-performance liquid chromatography 
(HPLC) pump along the modification process. The flow rate ranged from 10 to 300 μL min-
1
. 
 
2.5. Surface modification of central channel  
The CC of glass microfluidic immunosensor was exposed to a cleaning protocol, in 
which the solutions were pumped at flow rate of 2 µL min
-1
 as well as in all other 
procedures described in this section. As a first stage, CC was put in contact to 1:1 
methanol:HCl solution for 30 min. After this process an additional cleaning step was 
performed employing concentrated H2SO4 for 30 min. Each chemical treatment was 
followed by rinsing with deionized water and drying under N2. The described procedure 
effectively removes superficial contaminants and permits the homogeneous silanization of 
the glass surface. 
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Once the CC was in adequate conditions, the silanization process was carried out by 
exposing the CC to a 2% solution of 3-APTES in methanol for 1 h. This process was 
followed by three rinses with fresh methanol and dried under N2. This stage induces amine 
groups formation on the surface [18]. After that, glutaraldehyde solution (0.21 M) in 0.1 M 
sodium phosphate buffer (PBS, pH 8) was pumped to induce the formation of aldehyde 
groups at 25°C for 2 h. Then, the CC was exposed to a washing step with deionized water 
at 25°C for 1 h. As soon as, aldehyde groups were obtained on the glass surface, the 
immobilization of CuNPs-PVP (0.5 mg L
-1
) was performed at 25°C for 12 h according to 
the similar procedure proposed by Yu et al. (2007) [19].  
Later, CC was washed with 0.1 M PBS (pH 7.2) at 25°C for 1 h. Once CuNPs-PVP 
were covalently attached to CC, anti-GMN monoclonal antibodies (10 µg mL
−1 
0.01 M 
PBS, pH 7.2) were immobilized on their surface through the use of glutaraldehyde solution 
(0.21 M) in 0.1 M PBS (pH 8). In this case this cross-linker allowed the binding of the 
antibodies amino groups with those residual amino moieties present on the surface of 
CuNPs-PVP (Figure 1). Finally, the CC was rinsed with 0.1 M PBS (pH 7.2) to remove the 
unbound anti-GMN monoclonal antibodies and stored in the same buffer at 4°C. The 
overall time required for the immobilization procedure was 16 h. The immobilized 
monoclonal antibody preparation was stable for at least 1 month. 
Figure 1 
 
2.6. Analytical procedure for GMN determination 
The electrochemical determination of GMN was performed on: controls, samples 
and blank (0.01 M PBS, pH 7.2). To accomplish it, the solutions employed were injected 
using syringe pumps at a flow rate of 2 µL min
-1
. As a first step of each sample analysis, 
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the microfluidic immunosensor was exposed to a desorption buffer (0.1M glycine-HCl, pH 
2) for 5 min and then washed with PBS, pH 7.2 for 4 min. This treatment was carried out in 
order to desorb the immune-complex and start with a new analysis. After that, unspecific 
bindings were avoided by 5 min treatment with 1% bovine albumin in 0.01M PBS, pH 7.2 
and washed with 0.01 M PBS buffer (pH 7.2) for 4 min. Later, samples were injected into 
the PBS carrier for 10 min and then the immunosensor was washed with 0.01 M PBS, pH 
7.2 for 4 min. Once the GMN was recognized and captured by anti-GMN monoclonal 
antibody on CuNPs-PVP, the HRP-conjugated anti-GMN-antibody (dilution of 1/1500 in 
0.01 M PBS, pH 7.2) was added in the 0.01 M PBS (pH 7.2) for 5 min followed by a 
washing procedure with 0.01 M PBS, pH 7.2 for 4 min. Finally, the substrate solution (1 x 
10
-3
 M H2O2 and 1 x 10
-3
 M 4-TBC in 0.01 M phosphate–citrate buffer, pH 5) was pumped 
and the enzymatic product was detected at 
_
0.10 V (Figure 1).  
In order to start with the next determination of GMN, the microfluidic 
immunosensor was exposed to a desorption procedure (0.1 M glycine–HCl, pH 2) at a flow 
rate of 2 µL min
-1
 for 5 min and then washed with PBS, pH 7.2. The purpose of this 
treatment is to have immobilized capture monoclonal antibodies with free active sites 
before each sample analysis. The proposed device could be used with no significant loss of 
sensitivity for 15 days, whereas its useful lifetime was one month with a sensitivity 
decrease of 10%. The storage of the microfluidic immunosensor was made in 0.01 M PBS 
(pH 7.2) at 4ºC.  
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3. Results and discussion 
3.1. Characterization of synthesized CuNPs-PVP  
CuNPs-PVP obtained by a chemical reduction method have been characterized by 
UV-visible spectroscopy, SEM, EDS, TEM and FTIR. UV-visible absorption spectroscopy 
is widely being used technique to examine the optical properties of synthesized 
nanoparticles. Surface plasmon resonance (SPR) band at 550-650 nm in the UV-visible 
spectra indicates the formation of CuNPs-PVP [20]. Figure 2 (a) shows the characteristic 
SPR band at 630 nm indicating the formation of CuNPs-PVA [20]. This band presents a 
considerable width to speak of a polydispersity but in its characteristic range, these are 
spherical nanoparticles. 
Figure 2 (b) represents the SEM picture of CuNPs-PVP. This figure substantiates 
the approximate spherical shape to the nanoparticles, and also can be seen that the size of 
the nanoparticle is less than 20±5 nm [12-14, 16, 20, 21]. The elemental composition was 
disclosed by EDS analysis in which strong signals of Cu were observed at 8 keV, while 
signals from C and O were also recorded confirming the presence of CuNPs-PVP (Figure 2 
(c)) [20, 21]. Peaks of C and O reflecting the presence of elements constituting PVP. TEM 
image of CuNPs-PVP is showed in Figure 2 (d), revealing that the primary morphology of 
the nanoparticles is spherical. It can be seen that the nanoparticles are well dispersed, 
without aggregation and have small particle size in the range 10–25 nm. Small 
nanoparticles can be observed in Figure 2 (d), indicating good stabilization by the PVP. 
Moreover, the FTIR characterization was done by comparing two spectra, one of the PVP 
polymer and other of the PVP-stabilized nanoparticles, in order to obtain information of 
links involved in interactions (Figure 2 (e)). It is observed that the bands decreased in 
intensity when the nanomaterial is present with the PVP, producing interactions between 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
12 
 
both. The carbonyl band in the polymer alone appears at 1645 cm
-1
 while stabilizing the 
nanoparticles at slight shift occurs at 1643 cm
-1
 [22]. It is presumed that this link is 
responsible for interacting with the metal nanoparticles [23] leaving the carbon with a 
positive charge density, which is then stabilized by the free electron pair of the adjacent 
nitrogen in the ring, and then there is increase said signal of N-C from 1292 cm
-1
 for the 
PVP alone, to 1340 cm
-1
 when the CuNPs are linked. 
 
Figure 2 
 
3.2. Optimization of experimental variables 
Several studies of experimental variables that affect the performance of microfluidic 
immunosensor for GMN determination in biological samples were done. For this purpose a 
GMN control of 1.5 ng mL
-1
 was employed. One of the parameters evaluated was the 
optimal flow rate, which was determined by employing different flow rates and evaluating 
the current generated during the immune reaction. As shown in Figure S1 (Supplementary 
Material), flow rates from 1 to 2.5 μL min-1 had little effect over immune response and over 
signals obtained, whereas when the flow rate exceeded 3 μL min-1 the signal was 
dramatically reduced. Therefore, a flow rate of 2 μL min-1 was used for injections of 
samples, reagents and washing buffer.  
Figure S1 
The optimum reaction time was also evaluated, due to the fact that it affects the 
performance of the assay and consequently the obtained results. In order to optimize this 
factor, we analyzed different reaction times between the capture antibody and GMN in the 
developed microfluidic immunosensor through electrochemical signal. This first 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
13 
 
immunological stage was followed by adding HRP-conjugated anti-GMN-antibody. After 
washing, 4-TBC was incorporated. This enzymatic substrate suffered an oxidation process 
whose signal was measured as a function of reaction time. Figure 3 shows the obtained 
signals for 0.5, 1.5 and 2.5 ng mL
-1
 GMN control concentrations. The signal grew with 
increasing of the GMN concentration. As we estimated, the intensity of the electrochemical 
signal increased with the reaction time. However, the intensity of the signal did not 
markedly increase after 10 min for the higher GMN control concentration, which 
corresponds to the saturation of the antigen–antibody reaction in the microfluidic 
immunosensor. As a result, the reaction time used in all sample measurements was 10 min. 
Figure 3 
The determination of the optimum concentration of capture antibody to be 
employed in the immobilization procedure was also considered, due to the fact that the 
amount of this antibody affects the sensitivity of the immunoassay. The optimum value of 
anti-EpCAM recombinant antibody was 10 µg mL
-1
 (Supplementary Material). 
Finally, the rate of enzymatic response using a GMN control of 1.5 ng mL
-1 
under 
flow conditions was analyzed in the pH range of 4-7 and reached a maximum at pH 5. The 
pH value used was 5 in phosphate-citrate buffer (Figure S2, Supplementary Material). 
Figure S2 
 
3.3. Quantitative determination of GMN in the microfluidic immunosensor 
The determination of GMN was performed in 15 serum samples with the proposed 
method and under the optimized conditions. The calibration curve of the proposed 
immunosensor and commercial ELISA were constructed using different GMN control 
samples. The linear regression equation was i (nA) = 3.76 + 92.08 x CGMN, with the linear 
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regression coefficient r = 0.998. A linear relation was observed between the concentration 
range 0-2.5 ng mL
-1
. The coefficient of variation (CV) for the determination of 2.5 ng mL
-1
 
GMN was 3.76 % (five replicates). An ELISA procedure was also carried out plotting 
absorbance changes against the corresponding GMN concentration then, a calibration curve 
was constructed. The linear regression equation was A = 0.03 + 0.78 x CGMN, with the 
linear regression coefficient r = 0.996, and the CV for the determination of 2.5 ng mL
-1
 
GMN was 6.54 % (five replicates). The detection limit (LOD) was considered to be the 
concentration that gives a signal three times the standard deviation (SD) of the blank. For 
microfluidic immunosensor and commercial ELISA, the LODs were 0.23 ng mL
-1
 and 1 ng 
mL
-1
 respectively. This result shows that electrochemical detection was more sensitive than 
the spectrophotometric method. The precision of the proposed method was tested 
employing GMN controls of 0.5, 1.5 and 2.5 ng mL
-1
. The within-assay precision was 
tested with five measurements in the same run for each control. These series of analyses 
were repeated for three consecutive days to estimate between-assay precision. The results 
obtained are summarized in Table 1. The microfluidic immunosensor showed good 
precision; the CV within-assay values were below 3.95 % and the between assay values 
below 6.33 %.  
Table 1 
The accuracy was tested with a dilution test which was performed with a GMN 
control of 1.5 ng mL
−1
 which was serially diluted in 0.01 M PBS, pH 7.2. The linear 
regression equation was i (nA) = 0.01 + 144.72 x CGMN, with the linear regression 
coefficient r = 0.998 (Figure 4). 
Figure 4 
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Moreover, the proposed method was compared with a commercial ELISA procedure 
for the quantification of GMN in serum samples. The slopes obtained were reasonably 
close to 1, indicating a good correspondence between the two methods (Figure 5). For this 
comparison, 5 high level and 10 low level GMN serum samples were analyzed. These 
samples were previously confirmed using the commercial ELISA, which is currently used 
in clinical diagnostics. The high level samples were later analyzed by our proposed 
quantitative method, which revealed high concentrations of GMN in all of them. The low 
levels GMN serum samples and blanks were also confirmed by our proposed microfluidic 
immunosensor. The results obtained in Figure 5 correspond only to a modified CC of the 
proposed method. 
Figure 5 
 Microfluidic immunosensors are widely studied because of their relevant 
advantages. Some advantages of these methods include: compactness, low sample, low cost 
production, better general control of the process, in real time analysis and a quick response 
[24, 25]. These characteristics open the possibility of performing in situ, real-time 
measurements. Also, microfluidic immunosensors operate in such a manner that sample 
pre-treatment as well as chemical assay can be performed therein [26, 27]. Their ergonomic 
and user-friendly design allows being easily adapted to perform the desired analysis just by 
simply modifying the surface of the channels with nanomaterials as platform for the 
biomolecules immobilization [28]. Metal nanoparticles as such as CuNPs are beneficial for 
the development of biosensing techniques due to high surface areas, strong stability, limited 
aggregation, and high electrocatalytic activity [29]. Moreover, the electrochemical 
deposition of metal NPs into the microchannel can accurately control the position of 
nanostructures, maximize the stability of the electrode, and ensure that miniaturized 
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electrochemical sensors with NPs are more specific and highly sensitive for clinical 
diagnostics [30]. 
Furthermore, PVP is known to be a good stabilizer of small metal particles [30-33] 
and has been frequently used as particle stabilizers in chemical synthesis of different metal 
nanoparticles. Besides, this polymer combined with CuNPs can be easily integrated into 
microfluidic devices as nano-platform for biomolecules immobilization. 
 
4. Conclusions 
In the present work, we present an electrochemical microfluidic immunosensor 
based on CuNPs-PVP as nano-platform for immobilization of specific monoclonal 
antibodies applied to sensitive quantification of GMN in serum samples. The overall assay 
time employed (34 min) was shorter than the time reported for commercial ELISA test kit 
frequently used in clinical diagnosis (120 min), with no reduction on the sensibility and 
selectivity.  
Finally, our microfluidic immunosensor with CuNPs-PVP as immobilizing platform 
of specific monoclonal antibodies for GMN determination can be applied to the early 
diagnosis of IA. 
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Figure captions 
 
Figure 1. Representation of the glass microfluidic surface modification and the 
immunological reaction. Anti-GMN monoclonal antibodies were covalently bounded onto 
CuNPs-PVP, which were covalently attached over 3-APTES modified glass microfluidic 
surface. GMN present in the sample reacted immunologically with anti-GMN monoclonal 
antibody immobilized on CuNPs-PVP-3-APTES-modified glass microfluidic 
immunosensor. The bound GMN was quantified by HRP-conjugated anti-GMN antibody 
using 4-TBC as enzymatic mediator, which was oxidized on the electrode surface at -0.10 
V. The current magnitude was directly proportional to the level of GMN. 
Figure 2. Characterization of CuNPs-PVP nano-platform. (a) UV-visible spectra. (b) SEM 
image. This image confirmed the formation of spherical nanoparticles with a size <20±5 
nm. (c) EDS spectra for CuNPs-PVP. Peak of Cu were observed at 8 keV, while signals 
from C and O were also recorded confirming the presence of CuNPs-PVP. Peaks of C and 
O reflecting the presence of elements constituting PVP. (d) TEM image. (e) FTIR spectra.    
Figure 3. Study of reaction time effect using GMN controls of 0.5, 1.5, and 2.5 ng mL
-1
; 
0.01 M phosphate–citrate buffer, pH 5, containing 1 x 10-3 M H2O2 and 1 x 10
-3
 M 4-TBC 
were injected into the carrier stream at different flow rates, and the enzymatic product was 
measured on the electrode surface at -0.10 V. Each value of current is based on five 
determinations.  
Figure 4. Dilution test results for GMN control of 1.5 ng mL
-1
 in 0.01 M PBS, pH 7.2. 
Each value of current is based on five determinations.  
Figure 5. Correlation between proposed method and commercial ELISA. 
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Tables 
Table 1. Within-assay precision (five measurements in the same run for each control 
sample) and between-assay precision (five measurements for each control sample, repeated 
for three consecutive days).  
 
a
 Control sample Within-assay  Between-assay 
 Mean CV %  Mean CV % 
0.5 0.48 2.83  0.52 4,85 
1.5 1.48 3.95  1.53 5.63 
2.5 2.49 3.76  2.51 6.33 
a
 ng mL
-1 
GMN 
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Highlights 
• A novel microfluidic immunosensor for GMN quantification was developed. 
• This is based on the use of CuNPs-PVP as platform. 
• The electrochemical method presented a good analytical performance. 
• This device could be used for diagnosis of invasive aspergillosis. 
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